PT Quantum Clovera Investama Tbk EBIT

The latest EBIT for KREN.JK is $-180B as of June 2026. That compares with $-86B in the prior-year period — down 105.5% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside PT Quantum Clovera Investama Tbk's historical trend and sector peers before judging valuation or financial health.

Over the past year, KREN.JK's EBIT moved from $-86B to $-180B — a 105.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PT Quantum Clovera Investama Tbk's operating scale or balance-sheet position.

Against its sector companies, KREN.JK currently prints $-180B for EBIT, while the sector average sits near $2.6T. That is roughly 106.9% below the sector mean. Large gaps often invite a closer look at PT Quantum Clovera Investama Tbk's growth, margins, and balance sheet.

A EBIT figure of $-180B for KREN.JK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting KREN.JK's EBIT ($-180B), review year-over-year change from $-86B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.